At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. More commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emo...
At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health. Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. More commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity. Mycovia currently has three Phase 3 clinical studies being conducted to evaluate VT-1161 for the treatment of RVVC.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.